Sort   by:  
 Page size 
ProteomicsCombined Peptide array screen and proximity labeling proteomics fine map C/EBPa protein interactions
The pioneering transcription factor C/EBPα coordinates cell fate and cell differentiation. The structure of C/EBPα comprises intrinsically disordered regions, multiple short linear motifs, and extensive post-translational side chain modifications (PTM), reflecting its modularity and functional plast...
ORGANISM(S): Homo sapiens (Human) 
2021-07-12 | PXD022903 | Pride
Ptm Cebpa Bioid Peptide pulldowns 
ProteomicsA universal peptide matrix interactomics approach to disclose motif dependent protein binding
Protein-protein interactions (PPIs) mediated by intrinsically disordered regions (IDRs) are often based on short linear motifs (SLiM). SLiMs are implicated in signal transduction and gene regulation, yet remain technically laborious and notoriously challenging to study. Here, we present an optimized...
ORGANISM(S): Homo sapiens (Human) 
2021-08-11 | PXD027265 | Pride
Prisma Ptm Peptide interactomics 
ProteomicsProteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma
The immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide are highly effective treatments for multiple myeloma. However, virtually all patients eventually relapse due to acquired drug resistance with resistance-causing genetic alterations being found only in a small subset of cases. Here, we ...
ORGANISM(S): Homo sapiens (Human) 
2021-12-17 | PXD021265 | Pride
Multiple myeloma Tmt Lc-ms Cdk6 
ProteomicsSynergistic efficacy of combined SUMOylation and proteasome inhibition in multiple myeloma
Relapsed/refractory multiple myeloma (r/r MM) is a disease with often poor prognosis. Hyperactive SUMO signaling is involved in both cancer pathogenesis and cancer progression. A state of increased SUMOylation has been associated with aggressive cancer biology. Here, we found that r/r MM is characte...
ORGANISM(S): Homo sapiens (Human) 
2022-08-01 | PXD032316 | Pride
Proteasome inhibitor Myeloma Sumoylation inhibitor 
ProteomicsProteogenomic landscape of multiple myeloma
Multiple myeloma is a plasma cell malignancy of the bone marrow. Despite therapeutic advances, multiple myeloma remains incurable and better risk stratification as well as new therapies are therefore highly needed. The proteome of multiple myeloma has not been systematically assessed before and hold...
ORGANISM(S): Homo sapiens (Human) 
2024-07-09 | PXD038437 | Pride
Multiple myeloma Proteogenomics Plasma cells Therapeutic targets Clinical proteomics Risk signatures Biomarkers 
TranscriptomicsEffects of CEBPA isoform expression on NB4 cells
Here we investigated the effects of CEBPA transcription factor expression on myeloid NB4 cells. The sequence of rat CEBPA was C-terminally fused to a promiscuous biotin ligase tag (BirA*) and NB4 cell lines were engineered to express the fusion protein under the control of a doxycycline inducible p...
ORGANISM(S): Homo sapiens 
2021-06-26 | E-MTAB-9947 | biostudies-arrayexpress
Sort   by:  
 Page size